Therefore, a stepwise mode to select for gene mutations in NSCLC is suggested: first for KRAS, second for EGFR, EML4-ALK translocation, and then for concomitant EML4-ALK fusion and EGFR mutations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.